All In Biotech

NDA 017533 · Cheplapharm

Klonopin

Clonazepam · Oral · Benzodiazepine

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1975

Jun 4, 1975

Approved uses

2

Original approval plus efficacy supplements

Registered trials

53

9 Phase 3, 1 recruiting

FAERS reports

161,077

109,687 serious, 18,794 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS ). The use of benzodiazepines, including Klonopin, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing Klonopin and...

What it is approved for

From the label in effect Dec 1, 2025.

INDICATIONS AND USAGE Seizure Disorders Klonopin is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, Klonopin may be useful. Some loss of effect may occur during the course of clonazepam treatment (see PRECAUTIONS: Loss of Effect ). Panic Disorder Klonopin is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-V. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of Klonopin was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Panic disorder (DSM-V) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of Klonopin in long-term...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 9, 1997 Supplement 23 · Efficacy
  • Jun 4, 1975 Original approval · Type 1 - New Molecular Entity · priority review
5 products under this application
  • KLONOPIN · CLONAZEPAM 0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • KLONOPIN · CLONAZEPAM 1MG · TABLET, ORAL · Prescription · TE AB
  • KLONOPIN · CLONAZEPAM 0.125MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • KLONOPIN · CLONAZEPAM 2MG · TABLET, ORAL · Prescription · TE AB
  • KLONOPIN · CLONAZEPAM 0.5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Clonazepam" as an intervention, any sponsor and status, largest first.

All 53 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective14,148
  • fatigue10,591
  • nausea9,904
  • anxiety8,957
  • headache8,819
  • pain8,324
  • depression8,277
  • off label use8,149
  • dizziness7,466
  • insomnia7,179
  • dyspnoea7,174
  • fall6,901

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,222
20052,971
20062,758
20072,680
20083,066
20093,991
20105,734
20116,170
20127,037
20135,700
20146,969
201510,116
201611,568
201711,253
201810,777
201911,027
202010,609
20219,335
20228,694
20237,640
20247,565
20257,560
20265,630

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Resolved · updated Nov 4, 2026

    Klonopin, Tablet, 2 mg (NDC 61269-620-10).

  • Resolved · updated Nov 4, 2026

    Klonopin, Tablet, .5 mg (NDC 61269-605-10).

  • Resolved · updated Nov 4, 2026

    Klonopin, Tablet, 1 mg (NDC 61269-610-10).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Klonopin (Clonazepam)

2024 spending

$3.4M

Beneficiaries

2,323

14,868 claims

Per beneficiary

$1,466

$2.78 per unit

View as table
YearSpending
2020$4,568,132
2021$4,412,317
2022$3,663,256
2023$3,683,535
2024$3,405,214

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 365 on PubMed

Sponsor: Cheplapharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.